Cardiovascular DiseaseBATTLENCT00458874
Better Adherence to Therapeutic Lifestyle Change Efforts Trial
A study testing CIMT results in people with Cardiovascular Disease, run by Walter Reed National Military Medical Center at 1 site in United States.
Trial summary
The purpose of this study is to determine whether knowledge of abnormal results from a noninvasive test for detection of subclinical atherosclerosis (carotid intima media thickness [CIMT]), in addition to knowledge of cardiovascular disease (CVD) risk factors, enhances adherence to healthy lifestyle behaviors in… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cardiovascular Disease
- What is being tested?
- CIMT results
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 166 participants
- Where
- 1 siteUnited States
- Study dates
- Nov 2007to Apr 2011
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Military healthcare beneficiary
- Willing to modify current diet and exercise habits
- Two or more of following CVD risk factors (hypertension, hyperlipidemia, family history, tobacco use, BMI >/= 25 kg/m2)
- Metabolic syndrome
Who cannot join
- Clinical CVD or conditions that limit safe participation
- Individuals who participation would interfere with conduct of trial
- No significant preclinical atherosclerosis
Trial locations and contacts
1 site in 1 country.
United States1 site
Walter Reed National Military Medical Center / Integrative Cardiac Health Project (ICHP)
Bethesda, Maryland, 20889
About this study
Official title: Better Adherence to Therapeutic Lifestyle Change Efforts (BATTLE) Trial
The purpose of this study is to determine whether knowledge of abnormal results from a noninvasive test for detection of subclinical atherosclerosis (carotid intima media thickness [CIMT]), in addition to knowledge of cardiovascular disease (CVD) risk factors, enhances adherence to healthy lifestyle behaviors in comparison to only CVD risk factor knowledge. We believe that participants with CVD risk factors who have knowledge of their own CIMT test results showing significant subclinical atherosclerosis will demonstrate better adherence to therapeutic lifestyle change (TLC) than those subjects from whom the CIMT test information is withheld.
Read the detailed description
The outcomes of subjects randomized to receive their CIMT information (R-CIMT Group) will be compared to a control condition of subjects randomized to have their CIMT information withheld (W-CIMT Group) until the completion of a lifestyle intervention that is common to both groups. The rationale for this intervention is based on the Health Belief Model theory that risk awareness prompts action for behavioral change. In particular, our aim is to study the impact of a subject's own CIMT results, and not the impact of generic educational material related to CIMT and CHD risk, on adherence to a lifestyle change program. Subjects will not know the hypothesis of this study because this knowledge could potentially impact their behavior during the intervention. Also, subjects will not be told that only half of them will receive their CIMT information before the lifestyle intervention, since subjects could potentially infer the study hypothesis from this knowledge. To answer the question of whether CIMT results would be a useful motivational tool for adherence to lifestyle change recommendations, there needs to be a comparison group that does not have their CIMT results. Subjects will be clearly told in the consent process results that they may not receive results of their clinical testing, including the CIMT results, until the end of their participation in this study. Randomization will occur after subjects successfully complete a "run-in" period during screening, which introduces the lifestyle intervention and teaches the proper use of the data collection tools. At the beginning of each week in the randomized phase of the study, subjects will receive a confidential packet of scripted materials. Packets will contain identical information (e.g. educational materials, class schedules, feedback from diet/exercise logs) except that the R-CIMT group will also receive a report that contains a copy of one of their own ultrasound scans, with a comparison picture of a normal scan. This report will also include the CIMT thickness in each artery and an interpretation that states that their measurements are in the highest quartile for persons of their age and gender. Attached to the report will be a tutorial ("Interpreting Your CIMT Results") to more fully educate participants on detection of atherosclerosis with carotid ultrasound. Both the CIMT results report and the tutorial specifically couple the presence of significant subclinical atherosclerosis with increased risk for cardiovascular morbidity and mortality. (Appendix D). If subjects from whom CIMT information is withheld request their CIMT results during the study, they will be told that those results will be made available to them at the end of their participation in the study, which is consistent with the information they were given in the consent process. At the end of the study, subjects who were randomized to receive their CIMT information will be asked to complete a quiz (Atherosclerosis and CIMT Knowledge Assessment) to determine their comprehension of the CIMT information that had been provided to them at randomization (Appendix D).
Lifestyle Intervention
All randomized subjects will participate in a 12-week lifestyle intervention program that will be introduced and observed in the "run-in" period during screening. This intervention will incorporate strategies that have proven benefit in reduction of CVD risk including aerobic exercise, Mediterranean-type diet, and ongoing contact with weekly, on-site group sessions for lifestyle change education and support integrating Transtheoretical Stages of Change and Social Cognitive learning theories.74-76 To minimize the potential of unblinding research staff to the randomization assignment of a large number of subjects, subjects will enter the next available block of 12-weekly group sessions regardless of randomization assignment. To minimize the potential of unblinding study subjects to the study hypothesis, all subjects will be instructed to refrain from discussing any personal medical or information contained in their weekly packet received during the group support sessions. Randomization assignment will be known only to statistician/data management team.
Aerobic Exercise Physical activity is a pillar of any lifestyle intervention program because it improves cardiorespiratory and muscular fitness and promotes improvement of CHD risk factors including obesity, diabetes, hypertension, and hyperlipidemia. Based on each subject's baseline fitness and safety issues, a physical activity program (with a goal of 180 minutes of aerobic exercise per week by the end of the study) will be prescribed by an exercise physiologist and tailored to individual choices from various types of moderate intensity activities. Exercise is recommended to occur on most days of the week and for at least 10 minutes per session within a defined target heart rate range. After the "run-in" period, exercise will be unsupervised but assessed with a heart rate monitoring device and self-monitoring logs.
Diet A Mediterranean-type diet with caloric goals based on each subject's weight will be prescribed by a registered dietician. The composition of the diet is structured to encourage consumption of plant-based, minimally processed, seasonal foods including fruits, vegetables, whole grains, legumes, nuts, fish and poultry in preference to red meat, low-fat dairy products, and limited amounts of beneficial unsaturated oils such as olive oil. The recommended diet will have a maximum of 35% of total calories from fat, a maximum of 7% of total calories from saturated fat, and a minimum of 15% of total calories from protein. Subjects will be instructed in meal planning and food preparation. Structured menus will be offered as an option. Review of self-monitoring logs by the dietician will guide individual feedback during the "run-in" period and in the weekly communication packets during the randomized period.
Group Support Weekly on-site sessions will be held to stimulate social support for the lifestyle intervention. A structured curriculum focusing on goal setting, problem solving, and stress reduction will be presented by a trained facilitator with opportunity for open discussion. To reinforce the diet plan, a group meal and periodic food preparation demonstrations also will occur during these sessions.
- Conditions
- Cardiovascular Disease
- Being tested
- CIMT results
- Keywords
- CV risk factors, subclinical atherosclerosis, lifestyle intervention, motivation
- Medical subject headings
- Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CIMT resultsBehavioural
Both groups will receive a weekly confidential packet of scripted materials (e.g. educational materials, class schedules, feedback from diet/exercise logs). The R-CIMT group will also receive an CIMT report which contains a copy of one of their own ultrasound scans, with a comparison "normal" scan. This report will also include the CIMT thickness, an interpretation that states their measurements are in the highest quartile for persons of their age and gender, and associated CVD risk. "Interpreting Your CIMT Results" tutorial will be included in the first weekly packet to educate subjects on the detection of atherosclerosis with carotid ultrasound. The CIMT results are withheld from the W-CIMT group until the end of their study participation along with the CIMT tutorial.
| Study group | Role | What they receive |
|---|---|---|
| Receive CIMT Results (R-CIMT) | Experimental | This group will receive visual feedback of their CIMT results on a weekly basis. Receives: Behavioral: CIMT results |
| Withhold CIMT Results (W-CIMT) | No intervention | The W-CIMT group will not receive their CIMT results until the end of their study participation. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in lifestyle program adherence
A composite index of adherence to the TLC intervention was selected as the primary outcome measure since the main goal of this study is to assess the impact of CIMT imaging knowledge on change in lifestyle behaviors.
Measured: Baseline, Week 12
Secondary outcomes (7)
CVD risk factors
Measured: Baseline, 12 weeks
C-reactive protein
Measured: Baseline, Week 12
Anxiety
Measured: Baseline, Week 2, Week 12
Atherosclerosis and CIMT Knowledge
Knowledge test will be given to R-CIMT group only.
Measured: Week 12
Adherence to each lifestyle change program component
Adherence information will be collected on diet, exercise and attendance at weekly on-site sessions
Measured: Baseline, Week 12
Motivation
Measured: Baseline, Week 12
Self efficacy
Nutrition and exercise self-efficacy
Measured: Baseline, Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Apr 2007 (estimated)
- Study startNov 2007
- Primary completionJul 2010
- Study completionApr 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Cardiovascular DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 166 participants (actual)
Sponsor and investigators
- Lead sponsor
- Walter Reed National Military Medical Center
- Sponsor type
- US federal agency
- Collaborators
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Responsible party
- Sponsor
- Investigators
- Randolph Modlin, MD, Principal investigator, Walter Reed Army Medical CenterMarina N Vernalis, DO, FACC, Study director, Henry M. Jackson Foundation for the Advancement of Military Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00458874
- Sponsor's protocol ID
- WU#06-12025
- Acronym
- BATTLE
- Status last verified
- May 2016
- First submitted
- 9 Apr 2007
- Last updated
- 18 May 2016
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Publications
Walizer EM, Vernalis MN, Modlin RE. Influence of CIMT as a motivator for health behavior change in a heart health program. Circulation 2014;129:AP126.
Walizer EM, Vernalis MN, Modlin RE. Adherence to a lifestyle intervention program not improved by visual knowledge of carotid intima atherosclerosis. Circ Cardiovasc Qual Outcomes 2013;6:A43.
Walizer E, Kashani M, Eliasson A, Vernalis M. Integrative Cardiac Health Project risk score improves cardiovascular risk assessment in women with subclinical atherosclerosis. J Cardiovasc Nurs 2011; 26(4):265A.
Study at a glance
From the registry record, last updated by the sponsor on 18 May 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Better Adherence to Therapeutic Lifestyle Change Efforts (BATTLE) Trial
- ClinicalTrials.gov ID
- NCT00458874
- Acronym / sponsor ID
- BATTLE / WU#06-12025
- Conditions
- Cardiovascular Disease
- Keywords
- CV risk factors, subclinical atherosclerosis, lifestyle intervention, motivation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 166 participants (actual)
- Lead sponsor
- Walter Reed National Military Medical CenterUS federal agency
- Collaborators
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Study start
- Nov 2007
- Primary completion
- Jul 2010 (actual)
- Study completion
- Apr 2011 (actual)
- First posted
- 11 Apr 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine whether knowledge of abnormal results from a noninvasive test for detection of subclinical atherosclerosis (carotid intima media thickness [CIMT]), in addition to knowledge of cardiovascular disease (CVD) risk factors, enhances adherence to healthy lifestyle behaviors in comparison to only CVD risk factor knowledge. We believe that participants with CVD risk factors who have knowledge of their own CIMT test results showing significant subclinical atherosclerosis will demonstrate better adherence to therapeutic lifestyle change (TLC) than those subjects from whom the CIMT test information is withheld.
Detailed description
The outcomes of subjects randomized to receive their CIMT information (R-CIMT Group) will be compared to a control condition of subjects randomized to have their CIMT information withheld (W-CIMT Group) until the completion of a lifestyle intervention that is common to both groups. The rationale for this intervention is based on the Health Belief Model theory that risk awareness prompts action for behavioral change. In particular, our aim is to study the impact of a subject's own CIMT results, and not the impact of generic educational material related to CIMT and CHD risk, on adherence to a lifestyle change program. Subjects will not know the hypothesis of this study because this knowledge could potentially impact their behavior during the intervention. Also, subjects will not be told that only half of them will receive their CIMT information before the lifestyle intervention, since subjects could potentially infer the study hypothesis from this knowledge. To answer the question of whether CIMT results would be a useful motivational tool for adherence to lifestyle change recommendations, there needs to be a comparison group that does not have their CIMT results. Subjects will be clearly told in the consent process results that they may not receive results of their clinical testing, including the CIMT results, until the end of their participation in this study. Randomization will occur after subjects successfully complete a "run-in" period during screening, which introduces the lifestyle intervention and teaches the proper use of the data collection tools. At the beginning of each week in the randomized phase of the study, subjects will receive a confidential packet of scripted materials. Packets will contain identical information (e.g. educational materials, class schedules, feedback from diet/exercise logs) except that the R-CIMT group will also receive a report that contains a copy of one of their own ultrasound scans, with a comparison picture of a normal scan. This report will also include the CIMT thickness in each artery and an interpretation that states that their measurements are in the highest quartile for persons of their age and gender. Attached to the report will be a tutorial ("Interpreting Your CIMT Results") to more fully educate participants on detection of atherosclerosis with carotid ultrasound. Both the CIMT results report and the tutorial specifically couple the presence of significant subclinical atherosclerosis with increased risk for cardiovascular morbidity and mortality. (Appendix D). If subjects from whom CIMT information is withheld request their CIMT results during the study, they will be told that those results will be made available to them at the end of their participation in the study, which is consistent with the information they were given in the consent process. At the end of the study, subjects who were randomized to receive their CIMT information will be asked to complete a quiz (Atherosclerosis and CIMT Knowledge Assessment) to determine their comprehension of the CIMT information that had been provided to them at randomization (Appendix D).
Lifestyle Intervention
All randomized subjects will participate in a 12-week lifestyle intervention program that will be introduced and observed in the "run-in" period during screening. This intervention will incorporate strategies that have proven benefit in reduction of CVD risk including aerobic exercise, Mediterranean-type diet, and ongoing contact with weekly, on-site group sessions for lifestyle change education and support integrating Transtheoretical Stages of Change and Social Cognitive learning theories.74-76 To minimize the potential of unblinding research staff to the randomization assignment of a large number of subjects, subjects will enter the next available block of 12-weekly group sessions regardless of randomization assignment. To minimize the potential of unblinding study subjects to the study hypothesis, all subjects will be instructed to refrain from discussing any personal medical or information contained in their weekly packet received during the group support sessions. Randomization assignment will be known only to statistician/data management team.
Aerobic Exercise Physical activity is a pillar of any lifestyle intervention program because it improves cardiorespiratory and muscular fitness and promotes improvement of CHD risk factors including obesity, diabetes, hypertension, and hyperlipidemia. Based on each subject's baseline fitness and safety issues, a physical activity program (with a goal of 180 minutes of aerobic exercise per week by the end of the study) will be prescribed by an exercise physiologist and tailored to individual choices from various types of moderate intensity activities. Exercise is recommended to occur on most days of the week and for at least 10 minutes per session within a defined target heart rate range. After the "run-in" period, exercise will be unsupervised but assessed with a heart rate monitoring device and self-monitoring logs.
Diet A Mediterranean-type diet with caloric goals based on each subject's weight will be prescribed by a registered dietician. The composition of the diet is structured to encourage consumption of plant-based, minimally processed, seasonal foods including fruits, vegetables, whole grains, legumes, nuts, fish and poultry in preference to red meat, low-fat dairy products, and limited amounts of beneficial unsaturated oils such as olive oil. The recommended diet will have a maximum of 35% of total calories from fat, a maximum of 7% of total calories from saturated fat, and a minimum of 15% of total calories from protein. Subjects will be instructed in meal planning and food preparation. Structured menus will be offered as an option. Review of self-monitoring logs by the dietician will guide individual feedback during the "run-in" period and in the weekly communication packets during the randomized period.
Group Support Weekly on-site sessions will be held to stimulate social support for the lifestyle intervention. A structured curriculum focusing on goal setting, problem solving, and stress reduction will be presented by a trained facilitator with opportunity for open discussion. To reinforce the diet plan, a group meal and periodic food preparation demonstrations also will occur during these sessions.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Receive CIMT Results (R-CIMT) | Experimental | Behavioral: CIMT resultsThis group will receive visual feedback of their CIMT results on a weekly basis. |
| Withhold CIMT Results (W-CIMT) | No intervention | –The W-CIMT group will not receive their CIMT results until the end of their study participation. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Military healthcare beneficiary
- Willing to modify current diet and exercise habits
- Two or more of following CVD risk factors (hypertension, hyperlipidemia, family history, tobacco use, BMI >/= 25 kg/m2)
- Metabolic syndrome
Key exclusion criteria (3 listed)
- Clinical CVD or conditions that limit safe participation
- Individuals who participation would interfere with conduct of trial
- No significant preclinical atherosclerosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CIMT resultsBoth groups will receive a weekly confidential packet of scripted materials (e.g. educational materials, class schedules, feedback from diet/exercise logs). The R-CIMT group will also receive an CIMT report which contains a copy of one of their own ultrasound scans, with a comparison "normal" scan. This report will also include the CIMT thickness, an interpretation that states their measurements are in the highest quartile for persons of their age and gender, and associated CVD risk. "Interpreting Your CIMT Results" tutorial will be included in the first weekly packet to educate subjects on the detection of atherosclerosis with carotid ultrasound. The CIMT results are withheld from the W-CIMT group until the end of their study participation along with the CIMT tutorial. | Behavioural | Receive CIMT Results (R-CIMT) |
Primary outcome
Change in lifestyle program adherence
Time frame: Baseline, Week 12
A composite index of adherence to the TLC intervention was selected as the primary outcome measure since the main goal of this study is to assess the impact of CIMT imaging knowledge on change in lifestyle behaviors.
7 secondary outcomes
CVD risk factors
Time frame: Baseline, 12 weeks
C-reactive protein
Time frame: Baseline, Week 12
Anxiety
Time frame: Baseline, Week 2, Week 12
Atherosclerosis and CIMT Knowledge
Time frame: Week 12
Adherence to each lifestyle change program component
Time frame: Baseline, Week 12
Motivation
Time frame: Baseline, Week 12
Self efficacy
Time frame: Baseline, Week 12
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 May 2016.
- Results publicationWalizer EM, Vernalis MN, Modlin RE. Influence of CIMT as a motivator for health behavior change in a heart health program. Circulation 2014;129:AP126.
- Results publicationWalizer EM, Vernalis MN, Modlin RE. Adherence to a lifestyle intervention program not improved by visual knowledge of carotid intima atherosclerosis. Circ Cardiovasc Qual Outcomes 2013;6:A43.
- Results publicationWalizer E, Kashani M, Eliasson A, Vernalis M. Integrative Cardiac Health Project risk score improves cardiovascular risk assessment in women with subclinical atherosclerosis. J Cardiovasc Nurs 2011; 26(4):265A.
- Individual participant dataSharing planned: No
Related trials for Cardiovascular Disease
Active, not recruitingPhase 3
ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Ischemic Optic Neuropathy
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Randolph Modlin, MD principal investigator
Walter Reed Army Medical Center
Marina N Vernalis, DO, FACC study director
Henry M. Jackson Foundation for the Advancement of Military Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing CIMT results in people with Cardiovascular Disease, run by Walter Reed National Military Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 May 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in lifestyle program adherence (time frame: Baseline, Week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00458874, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2016.